{"filings":[{"id":99891,"accession_number":"0001628280-26-030677","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q2 revenue $145M, GAAP EPS -$3.41; cuts FY2026 guidance, extends long-range plan to 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Organic revenue declined 3% YoY; $149M non-cash goodwill impairment on Multiomics unit.","FY2026 organic growth guidance cut to -2% to +1% (prev. 3-5%); Adj. EBITDA margin now -125bps to flat.","Long-range plan extended from 2028 to 2029; B Medical Systems sale delayed due to buyer financing.","Non-GAAP diluted EPS -$0.04 vs. +$0.01 prior year; cash and securities $565M; no share repurchases yet."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":293437000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99890,"accession_number":"0001437749-26-011542","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Azenta appoints Trey Martin as Multiomics President; Ginger Zhou steps down","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Trey Martin appointed President of Multiomics effective April 6, 2026; reports to CEO John Marotta.","Martin most recently served as CEO of Maravai LifeSciences (MRVI) and previously led IDT under Danaher (DHR).","Ginger Zhou stepped down as President; she will remain as advisor through November 2026 under a consulting agreement with $103,500 initial fee.","Executive officers Lawrence Lin, Ephraim Starr, and Olga Pirogova received amended offer letters clarifying severance and change-in-control terms.","Azenta aims to accelerate Multiomics long-range plan focusing on global synthesis scale, operational excellence, and profitable growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99889,"accession_number":"0001437749-26-011121","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Azenta says B Medical Systems sale to Thelema did not close by March 31 due to buyer financing failure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Thelema informed Azenta on March 27, 2026 that financing for the B Medical Systems acquisition has not been secured.","Transaction did not close by the expected March 31, 2026 deadline; agreement remains in place but no assurance of completion.","Parties have not amended or terminated the agreement as of the filing date.","Azenta is evaluating potential paths forward while Thelema continues to pursue financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116174,"accession_number":"0001437749-26-006821","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Azenta acquires UK Biocentre for GBP 20.5M to expand European biorepository footprint","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration of GBP 20.5M net of cash, including up to GBP 1.8M contingent milestone payments.","UK Biocentre generated approx GBP 15.3M revenue in twelve months ended Sep 30, 2025.","Deal expected to be dilutive to FY2026 Adj EBITDA margin by ~35bps, accretive to FY2027/2028 revenue growth and margin.","UK Biocentre will operate as European hub, adding automated high-throughput capacity and BioArc™ Ultra deployment.","Conference call to discuss transaction scheduled for March 10, 2026 at 10:00 am ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116173,"accession_number":"0001437749-26-002876","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q1 revenue $149M flat; GAAP EPS -$0.11; non-GAAP EPS $0.09; reaffirms FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $149M (+1% YoY); organic revenue -1%. Sample Mgmt $81M flat; Multiomics $67M (+1%).","GAAP diluted EPS from continuing ops -$0.11 (vs -$0.16); total diluted EPS -$0.34. Non-GAAP EPS $0.09 (vs $0.12).","Gross margin 42.9% (down 380bps) on lost leverage & rework costs; operating margin -4.9%.","Adjusted EBITDA $13M, margin 8.5% (down 230bps). Board authorized $250M share repurchase program through Dec 2028.","Definitive agreement to sell B Medical Systems for $63M; close expected by March 31, 2026. FY2026 guidance reaffirmed: organic rev growth 3-5%, ~300bps adj EBITDA margin expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":148642000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116172,"accession_number":"0001437749-26-002593","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Alan P. Malus resigns from Azenta Board effective Jan 29, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Malus resigned due to full-time commitments at another company.","He also served on the Human Resources and Compensation Committee.","Resignation not due to any disagreement with Azenta or its Board.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116171,"accession_number":"0001437749-26-002409","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Azenta stockholders elect directors, approve equity plan amendment and say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected; Dipal Doshi received 32,984,474 votes for.","Say-on-pay advisory vote passed with 38,413,005 votes for (approx. 96% of votes cast).","2020 Equity Incentive Plan amended to increase share reserve by 2,750,000; approved with 38,069,842 votes for.","Ratification of PwC as auditor for FY2026 passed with 42,222,109 votes for.","Broker non-votes of 2,380,543 on director elections, say-on-pay, and equity plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132617,"accession_number":"0001437749-25-038787","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Azenta sells B Medical Systems to related-party Thelema for $63M; close by Mar 31, 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale of B Medical Systems subsidiary to Thelema S.À R.L. for USD 63M; Thelema is majority-owned by Azenta VP & B Medical CEO Luc Provost.","Thelema deposited $9M; remaining $54M due on or before Mar 31, 2026, subject to securing final residual financing.","If financing condition not satisfied by Mar 31, 2026, Azenta retains $5M break-up fee and may terminate.","Proceeds to be deployed to strengthen company and drive long-term shareholder value, per CEO John Marotta."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132616,"accession_number":"0001437749-25-037345","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Azenta authorizes $250M share repurchase program through 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $250M of common stock, effective Dec 9, 2025 through Dec 31, 2028.","Repurchases may be via open market, private transactions, ASRs, or 10b5-1 plans; no obligation to buy specific amount.","CEO cites four-part capital allocation strategy: productivity, organic growth, M&A, and share repurchases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132615,"accession_number":"0001437749-25-035905","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q4 revenue $159M, +6% YoY; FY2026 guidance 3-5% organic growth, margin expansion 300 bps","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $159M, +6% YoY (organic +4%); FY revenue $594M, +4% (organic +3%).","Q4 GAAP diluted EPS from continuing ops $1.11 vs -$0.04 YoY; non-GAAP EPS $0.21 vs $0.19.","FY Adjusted EBITDA margin 11.2%, +310 bps YoY; Q4 margin 13.0%.","FY2026 guidance: organic revenue growth 3-5%, Adj. EBITDA margin expansion ~300 bps.","One-time $45.6M tax benefit from worthless stock deduction boosted Q4 EPS."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":593821000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149141,"accession_number":"0001437749-25-024705","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q3 revenue flat at $144M; non-GAAP EPS $0.19 vs $0.14 YoY; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $144M flat YoY; organic revenue down 2%. Sample Management Solutions -4%, Multiomics +4%.","Non-GAAP diluted EPS $0.19 (vs $0.14); GAAP EPS from cont ops $0.01 (vs ($0.00)).","Adjusted EBITDA $18M, margin 12.3% (+260 bps); operating cash flow $26M, FCF $15M.","FY2025 guidance reaffirmed: organic growth 3-5% and ~300 bps EBITDA margin expansion.","Discontinued ops (B Medical) $50M non-cash impairment; total diluted EPS ($1.15)."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":434870000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149140,"accession_number":"0001437749-25-021973","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Azenta VP and Chief Accounting Officer Violetta Hughes resigns effective Aug 6, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Violetta Hughes, VP and Chief Accounting Officer, voluntarily resigns effective August 6, 2025.","Resignation is not due to any disagreement with the Company or Board on operations, policies, or accounting matters.","Hughes will stay through the separation date to ensure a smooth transition of responsibilities.","She is resigning to pursue opportunities outside of the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168146,"accession_number":"0001437749-25-017419","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Azenta GC Jason Joseph departs; Ephraim Starr appointed as General Counsel","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason W. Joseph to cease as SVP, General Counsel & Secretary on May 15, 2025; employment ends June 30, 2025.","Joseph receives accelerated RSU vesting (Aug 2024 grant), bonus for FY2025, and continued vesting through consulting period to Nov 30, 2025.","Ephraim Starr appointed as SVP, General Counsel & Secretary effective May 15, 2025.","Starr previously GC at PHC Holdings, VP & GC at Danaher Water Quality, and senior legal roles at Lenovo, Honeywell, Kirkland & Ellis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168145,"accession_number":"0001437749-25-014901","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q2 revenue $143M up 5% YoY; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $143M (+5% YoY, organic +6%); Sample Mgmt Solutions $80M (+8%), Multiomics $64M (+2%).","GAAP diluted EPS from continuing ops -$0.40 (vs -$0.29); total diluted EPS -$0.88 (vs -$2.47).","Non-GAAP diluted EPS $0.05 (vs $0.06); Adjusted EBITDA $14M, margin 10.0% (up 400bps YoY).","Cash & marketable securities $540M; operating cash flow $14M, free cash flow $7M in quarter.","FY2025 guidance reaffirmed: organic revenue growth 3–5%, Adjusted EBITDA margin expansion ~300 bps."],"consensus_eps_estimate":0.1395,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":290928000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168144,"accession_number":"0001437749-25-011527","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Azenta President of Sample Management Solutions David Wang departs; consultant role through Dec 9","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["President of Sample Management Solutions David Wang's employment ends April 9, 2025; consulting period runs through December 9, 2025.","Mr. Wang to receive pro-rated FY2025 bonus, full vesting of 6,333 RSUs from Aug 2024 grant, and continued vesting on other awards.","Separation is amicable with signed severance agreement including release of claims and consulting services.","No successor named for the President of Sample Management Solutions role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185352,"accession_number":"0001437749-25-002824","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","5.07","9.01"],"status":"ready","headline":"Azenta Q1 FY25 revenue rises 4% YoY to $148M; adjusted EBITDA margin improves 400 bps to 9.0%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS from continuing ops -$0.21 (vs -$0.13 YoY); total diluted EPS -$0.29 (vs -$0.28).","Non-GAAP diluted EPS unchanged at $0.08; adjusted EBITDA $13M vs $7M in prior year.","Sample Management Solutions revenue $81M (+3% YoY); Multiomics $66M (+6% YoY).","Reaffirmed FY2025 guidance: organic revenue growth 3-5%, adjusted EBITDA margin expansion ~300 bps.","Free cash flow $22M; cash and marketable securities $530M including $27M from discontinued ops."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":147510000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185351,"accession_number":"0001437749-25-002273","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta recasts historical financials to reflect B Medical Systems as discontinued operations held for sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["For FY2024 (12 months ended Sep 30, 2024), continuing ops revenue $573.2M, operating loss $50.6M.","Discontinued ops (B Medical) posted net loss of $140.5M for FY2024, classified as held for sale since Nov 12, 2024.","Recast data covers multiple prior periods to help investors isolate core Sample Management & Multiomics segments.","Sale of B Medical is intended to simplify portfolio and focus on core revenue growth and profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201934,"accession_number":"0001437749-24-034563","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Azenta reports Q4 FY2024 revenue $170M; plans to sell B Medical; appoints Lawrence Lin CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 combined Sample Mgmt & Multiomics organic revenue grew 4%; Q4 organic growth 5%.","Full year Adjusted EBITDA margin expanded ~300 bps to 7.5%; FY2025 guidance: 3-5% organic revenue growth and ~300 bps margin expansion.","Board pursuing sale of B Medical Systems segment to simplify portfolio and focus on core businesses.","Lawrence Lin appointed CFO effective after FY2024 10-K filing; Herman Cueto to serve as advisor through Q1 FY2025.","Completed $1.5B share repurchase program, repurchasing 30M shares through September 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":656323000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201933,"accession_number":"0001437749-24-033059","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Azenta appoints Cornog, Koffey, Malus to board; forms Value Creation Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appoints William Cornog (ex-KKR Capstone), Alan Malus (ex-Thermo Fisher EVP), and activist Quentin Koffey (Politan, 9.4% owner) as independent directors.","Board expands from 9 to 12; new Value Creation Committee to advise on growth, cost, and capital deployment, chaired by Cornog.","Cooperation agreement with Politan includes standstill and voting provisions through October 2025; Koffey joins compensation committee.","Two current directors will not stand for re-election at the 2025 annual meeting.","Reaffirms full-year 2024 financial guidance provided on August 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217979,"accession_number":"0001437749-24-028399","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Azenta appoints John Marotta as President and CEO; Schwartz retires after 14-year tenure","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Marotta becomes President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz.","Marotta previously Executive in Residence at Patient Square Capital and CEO of PHC Holdings.","Marotta's compensation: $900k base salary, 110% target bonus, equity grants worth ~$7.85M (performance/time-based RSUs).","Dr. Schwartz to serve as advisor until Nov 2025: $66,250/month through Mar 2025, then $33,333/month.","Board increased from 8 to 9 members; Marotta appointed to Board effective Start Date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217978,"accession_number":"0001437749-24-024893","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q3 revenue $173M (+4% YoY); non-GAAP EPS $0.16 beat; FY revenue guidance cut but EBITDA margin expansion raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $173M, up 4% YoY, organic growth 5%. Sample Mgmt Solutions $81M (+7%), Multiomics $64M (flat), B Medical $29M (+7%).","GAAP diluted EPS from continuing ops -$0.12; non-GAAP diluted EPS $0.16 vs $0.13 prior year. Adjusted EBITDA $18M, margin 10.3% (+260bps YoY).","FY2024 revenue guidance lowered to $652-658M (organic down 1-2%); adjusted EBITDA margin expansion ~300bps; non-GAAP EPS guidance raised to $0.30-$0.36.","Repurchased 4.2M shares for $225.9M in Q3; expects to complete remaining $1.5B authorization by Oct 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":486260000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237912,"accession_number":"0001558370-24-007472","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Azenta CEO Stephen Schwartz retiring; board initiates search for successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Schwartz retires as CEO and director effective May 7, 2024; will continue until successor appointed.","Board reduced from nine to eight members; Heidrick & Struggles retained for CEO search.","Transition agreement provides continued base salary, equity vesting, and potential consulting role post-transition.","Azenta also reported Q2 fiscal 2024 earnings results (no specific figures in this filing)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237911,"accession_number":"0001558370-24-007348","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q2 revenue $159M (+7%); non-GAAP EPS $0.05; $111M goodwill impairment; guides FY rev lower","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $159M, up 7% YoY; organic growth 7%; B Medical revenue up 51% to $23M.","GAAP diluted EPS from continuing ops ($2.47) vs ($0.03); includes $111.3M non-cash goodwill impairment in B Medical.","Non-GAAP diluted EPS $0.05 vs ($0.06); adjusted EBITDA $9M vs ($2M); margin 5.9% up 750 bps.","FY2024 rev guidance lowered to $659-$671M (organic -1% to +1%); non-GAAP EPS raised to $0.27-$0.37.","Repurchased 1.2M shares for $73.9M in Q2; $1.025B used of $1.5B authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":313451000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}